STOCK TITAN

Avalo Therapeutics (AVTX) DEF 14A Filings

AVTX NASDAQ

Here are the DEF 14A proxy statements from Avalo Therapeutics, Inc. (AVTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.

Rhea-AI Summary

Avalo Therapeutics, Inc. is holding a virtual 2026 Annual Meeting of Stockholders on June 2, 2026, for holders of 26,714,337 common shares as of April 6, 2026. Stockholders will vote on electing seven directors, approving a Second Amended and Restated 2016 Employee Stock Purchase Plan, and ratifying Ernst & Young LLP as independent auditor for 2026.

The updated employee stock purchase plan would keep 961,608 shares available and add an annual “evergreen” increase from 2027 through 2036, capped at the lesser of 1% of specified equity outstanding or 4,000,000 shares per year. The proxy also outlines Avalo’s board independence, committee structure, director compensation, and governance policies.